Dale G Ando - Net Worth and Insider Trading

Dale G Ando Net Worth

The estimated net worth of Dale G Ando is at least $50,152 dollars as of 2024-04-18. Dale G Ando is the VP, Therapeutic Dev. & CMO of Sangamo Therapeutics Inc and owns about 96,763 shares of Sangamo Therapeutics Inc (SGMO) stock worth over $50,152. Details can be seen in Dale G Ando's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Dale G Ando has not made any transactions after 2015-06-05 and currently still holds the listed stock(s).

Transaction Summary of Dale G Ando

To

Dale G Ando Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Dale G Ando owns 1 companies in total, including Sangamo Therapeutics Inc (SGMO) .

Click here to see the complete history of Dale G Ando’s form 4 insider trades.

Insider Ownership Summary of Dale G Ando

Ticker Comapny Transaction Date Type of Owner
SGMO Sangamo Therapeutics Inc 2015-06-05 VP & Therapeutic Dev. & CMO

Dale G Ando Latest Holdings Summary

Dale G Ando currently owns a total of 1 stock. Dale G Ando owns 96,763 shares of Sangamo Therapeutics Inc (SGMO) as of June 5, 2015, with a value of $50,152.

Latest Holdings of Dale G Ando

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SGMO Sangamo Therapeutics Inc 2015-06-05 96,763 0.52 50,152

Holding Weightings of Dale G Ando


Dale G Ando Form 4 Trading Tracker

According to the SEC Form 4 filings, Dale G Ando has made a total of 0 transactions in Sangamo Therapeutics Inc (SGMO) over the past 5 years. The most-recent trade in Sangamo Therapeutics Inc is the sale of 15,000 shares on June 5, 2015, which brought Dale G Ando around $184,350.

Insider Trading History of Dale G Ando

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Dale G Ando Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Dale G Ando Ownership Network

Ownership Network List of Dale G Ando

No Data

Ownership Network Relation of Dale G Ando


Dale G Ando Owned Company Details

What does Sangamo Therapeutics Inc do?

Who are the key executives at Sangamo Therapeutics Inc?

Dale G Ando is the VP & Therapeutic Dev. & CMO of Sangamo Therapeutics Inc. Other key executives at Sangamo Therapeutics Inc include 10 percent owner Biogen Inc. , SVP-Chief Development Officer Nathalie Dubois-stringfellow , and 10 percent owner Biogen Ma Inc. .

Sangamo Therapeutics Inc (SGMO) Insider Trades Summary

Over the past 18 months, Dale G Ando made no insider transaction in Sangamo Therapeutics Inc (SGMO). Other recent insider transactions involving Sangamo Therapeutics Inc (SGMO) include a net sale of 6,000,000 shares made by Biogen Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Sangamo Therapeutics Inc (SGMO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,000,000 shares of Sangamo Therapeutics Inc (SGMO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 6,000,000 shares.

Sangamo Therapeutics Inc (SGMO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Sangamo Therapeutics Inc Insider Transactions

No Available Data

Dale G Ando Mailing Address

Above is the net worth, insider trading, and ownership report for Dale G Ando. You might contact Dale G Ando via mailing address: C/o Cell Genesys Inc, 500 Forbes Blvd, South San Francisco Ca 94080.

Discussions on Dale G Ando

No discussions yet.